Catawba Capital Management VA lowered its holdings in Novartis AG (NYSE:NVS) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,308 shares of the company’s stock after selling 1,865 shares during the quarter. Catawba Capital Management VA’s holdings in Novartis were worth $2,461,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of NVS. WFG Advisors LP raised its holdings in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after buying an additional 337 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis in the 3rd quarter valued at $106,000. Cable Hill Partners LLC raised its holdings in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after buying an additional 1,107 shares during the period. Harding Loevner LP purchased a new stake in shares of Novartis in the 2nd quarter valued at $146,000. Finally, Sawyer & Company Inc purchased a new stake in shares of Novartis in the 4th quarter valued at $183,000. Institutional investors own 10.85% of the company’s stock.
Several research firms recently issued reports on NVS. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Thursday. UBS Group reiterated a “neutral” rating on shares of Novartis in a report on Monday. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. Novartis presently has a consensus rating of “Hold” and a consensus price target of $85.32.
Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The firm had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. During the same period in the previous year, the firm posted $1.23 EPS. Novartis’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts anticipate that Novartis AG will post 4.79 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3146122/novartis-ag-nvs-shares-sold-by-catawba-capital-management-va.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.